We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$219M
AUM Growth
+$3.33M
Cap. Flow
-$9.09M
Cap. Flow %
-4.16%
Top 10 Hldgs %
53.49%
Holding
80
New
23
Increased
12
Reduced
26
Closed
8
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
RDUS icon
Radius Health, Inc.
RDUS
+$4.26M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$3.77M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.35M
4
SAGE icon
Sage Therapeutics
SAGE
+$3.05M
5
SNY icon
Sanofi
SNY
+$2.95M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$9.92M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.66M
3
ENSG icon
The Ensign Group
ENSG
+$5.27M
4
ARRY icon
Array Biopharma Inc
ARRY
+$4.92M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$3.72M

Sector Composition

Rank Sector Weight
1 Healthcare 72.69%
2 Real Estate 11.35%
3 Industrials 8.34%
4 Miscellaneous 6.63%
5 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
QCP
1
DELISTED
Quality Care Properties, Inc.
QCP
$23.1M 10.57%
1,074,080
+43,419
+4% +$916K
2017 Q4
2 quarters
RCM icon
2
DELISTED
R1 RCM Inc. Common Stock
RCM
$15.7M 7.18%
1,808,076
-101,811
-5% -$824K
2017 Q4
2 quarters
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
$15.3M 7.01%
226,902
+16,124
+8% +$902K
2017 Q4
2 quarters
RDUS icon
4
DELISTED
Radius Health, Inc.
RDUS
$13.8M 6.32%
468,581
+134,843
+40% +$4.26M
2017 Q4
2 quarters
GSK icon
5
GSK
GSK
$99.6B
$10.3M 4.72%
202,067
+20,800
+11% +$1.05M
2018 Q1
1 quarter
SNY icon
6
Sanofi
SNY
$96.9B
$8.52M 3.9%
212,972
+75,000
+54% +$2.95M
2017 Q4
2 quarters
SPY icon
7
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$812B
$8.14M 3.72%
30,000
-30,000
-50% -$8.1M
2017 Q4
2 quarters
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$10.7B
$7.94M 3.63%
84,257
+38,257
+83% +$3.35M
2017 Q4
2 quarters
TLGT
9
DELISTED
Teligent, Inc
TLGT
$7.31M 3.34%
211,210
+56,172
+36% +$1.77M
2017 Q4
2 quarters
SAGE icon
10
DELISTED
Sage Therapeutics
SAGE
$6.79M 3.11%
43,401
+19,401
+81% +$3.05M
2018 Q1
1 quarter
ZGNX
11
DELISTED
Zogenix, Inc.
ZGNX
$6.67M 3.05%
150,845
-53,701
-26% -$2.21M
2017 Q4
2 quarters
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.5B
$6.25M 2.86%
63,493
-15,400
-20% -$1.53M
2018 Q1
1 quarter
ENSG icon
13
The Ensign Group
ENSG
$10.4B
$5.96M 2.72%
177,540
-170,844
-49% -$5.27M
2017 Q4
2 quarters
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$128B
$5.92M 2.71%
34,822
-10,000
-22% -$1.55M
2017 Q4
2 quarters
ARNA
15
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.85M 2.68%
134,151
-86,637
-39% -$3.72M
2018 Q1
1 quarter
ZGNX
16
PUT
DELISTED
Zogenix, Inc.
ZGNX
$5.45M 2.49%
+123,300
New +$5.08M
2018 Q2
0 quarters
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.84B
$5.29M 2.42%
+40,000
New +$3.77M
2018 Q2
0 quarters
NVRO icon
18
DELISTED
NEVRO CORP.
NVRO
$3.78M 1.73%
47,279
-13,571
-22% -$1.13M
2017 Q4
2 quarters
ABT icon
19
Abbott
ABT
$181B
$2.8M 1.28%
45,900
-2,000
-4% -$121K
2018 Q1
1 quarter
ATHN
20
DELISTED
Athenahealth, Inc.
ATHN
$2.55M 1.16%
+16,000
New +$2.37M
2018 Q2
0 quarters
TSRO
21
DELISTED
TESARO, Inc.
TSRO
$2.34M 1.07%
52,523
+1,000
+2% +$48.6K
2017 Q4
2 quarters
ANAB icon
22
AnaptysBio
ANAB
$1.43B
$2.32M 1.06%
+32,634
New +$2.74M
2018 Q2
0 quarters
ABMD
23
DELISTED
Abiomed Inc
ABMD
$2.29M 1.05%
5,594
-1,500
-21% -$543K
2017 Q4
2 quarters
APLS icon
24
DELISTED
Apellis Pharmaceuticals
APLS
$2.16M 0.99%
+98,395
New +$2.26M
2018 Q2
0 quarters
ARQL
25
DELISTED
Arqule Inc
ARQL
$2.07M 0.95%
+374,320
New +$1.43M
2018 Q2
0 quarters
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Eversept Partners held 80 positions worth $219M, up 1.5% from $215M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Eversept Partners withdrew a net $9.09M in Q2 2018, closing 8 positions and reducing 26 holdings. Its most notable exit was Ablynx NV, an estimated $9.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 75% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Eversept Partners opened a new position in Sarepta Therapeutics worth $5.29M.

  • Eversept Partners's largest Q2 2018 buy was Sarepta Therapeutics: 40,000 shares worth $5.29M.
  • Eversept Partners added most to Radius Health, Inc. in Q2 2018, an estimated $4.26M increase.
  • Eversept Partners's biggest Q2 2018 reduction was The Ensign Group, cutting an estimated $5.27M.
  • Eversept Partners fully exited Ablynx NV in Q2 2018, selling an estimated $9.92M.
  • Eversept Partners's ten largest holdings make up 53% of its $219M portfolio in Q2 2018.
  • Eversept Partners opened 23 new positions and closed 8 in Q2 2018.
  • Eversept Partners's portfolio value rose 1.5% quarter-over-quarter to $219M.

Based on Eversept Partners's 13F filing for Q2 2018, filed 14 Aug 2018.